Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Small cell lung cancer
Tarlatamab (DLL3×CD3 BiTE) MAIC suggests OS edge vs paclitaxel/CAV in platinum-refractory ES-SCLC
Tarlatamab is a DLL3×CD3 bispecific T-cell engager (BiTE) that redirects cytotoxic T cells to DLL3-expressing SCLC cells; here, an unanchored matching-adjusted indirect comparison (MAIC) used DeLLphi-304 individual…
NCT05740566 - Trial result Spotlight
Bladder and urothelial cancer
Enfortumab vedotin (Nectin-4 ADC) + pembrolizumab (PD-1) sustains 33.6-mo OS and high CR conversion vs platinum chemo in 1L la/mUC
Enfortumab vedotin is a Nectin-4–directed antibody–drug conjugate (MMAE payload) combined with pembrolizumab, a PD-1 inhibitor; in the randomized Phase 3 EV-302/KEYNOTE-A39 trial (NCT04223856), previously untreated…
NCT04223856 - Trial result
Bladder and urothelial cancer
PPM (PLZ4-targeted paclitaxel micelles) shows early complete remissions with clean safety in BCG-unresponsive NMIBC
PLZ4-coated paclitaxel-loaded micelles (PPM) are a solvent-free, intravesical nanoparticle designed to selectively bind bladder cancer cells (via the PLZ4 peptide) and deliver encapsulated paclitaxel for local…
NCT05519241 - Trial result Spotlight
Neuroendocrine and adrenal tumors
[177Lu]Lu-edotreotide (SSTR2-targeted PRRT) beats everolimus on PFS in progressive GEP-NETs (COMPETE)
[177Lu]Lu-edotreotide is a somatostatin receptor (SSTR; high affinity for SSTR2)–targeted peptide receptor radionuclide therapy (PRRT; [177LuDOTA]-TOC) compared head-to-head with everolimus (oral mTOR inhibitor) in…
NCT03049189 - Trial result Spotlight
Colorectal cancer
Toripalimab (PD-1) + celecoxib (COX-2) lifts pCR to 89% in dMMR/MSI-H locally advanced CRC (PICC-2)
Toripalimab is an anti–PD-1 monoclonal antibody, and celecoxib is an oral COX-2 inhibitor hypothesized to reshape the inflammatory tumor microenvironment to potentiate checkpoint blockade. In the open-label,…
NCT03926338 - Trial result
Colorectal cancer
CapeOx “sandwich” TNT (fluoropyrimidine/oxaliplatin + RT) drives 46.9%cCR and 46.4%pCR in low-risk distal LARC
CapeOx (capecitabine + oxaliplatin) is a fluoropyrimidine/platinum doublet used here as a “sandwich” total neoadjuvant therapy (TNT) backbone, delivered as 2 cycles before, during, and after long-course radiotherapy,…
NCT03840239 - Trial result Spotlight
Breast cancer
Inavolisib (PI3Kα inhibitor/p110α degrader) more than doubles PFS vs placebo in Asian PIK3CA-mut HR+/HER2– aBC
In the Phase 3 INAVO120 trial (NCT04191499), inavolisib (INAVO) is an oral, selective PI3Kα inhibitor that also promotes degradation of mutant p110α, combined with palbociclib (CDK4/6 inhibitor) plus fulvestrant…
NCT04191499 - Trial result Spotlight
Breast cancer
Durvalumab (PD-L1) + trastuzumab deruxtecan (HER2 ADC) delivers 62% ORR but 21% ILD in 1L HR−/HER2-low mBC
Durvalumab is an anti–PD-L1 checkpoint inhibitor and trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload; the combo was tested as first-line…
NCT03742102 - Trial result
Breast cancer
Tucatinib + T-DXd posts 51% ORR in pretreated HER2+ metastatic breast cancer
Tucatinib is an oral HER2-selective TKI combined here with trastuzumab deruxtecan, a HER2-directed antibody–drug conjugate carrying a topoisomerase I payload, in the single-arm, open-label Phase 2 HER2CLIMB-04 trial…
NCT04539938 - Trial result
Breast cancer
Bria-IMT (SV-BR-1-GM whole-cell vaccine + GM-CSF) + PD-1 blockade shows 44% 12-mo OS in heavily pretreated MBC
Bria-IMT pairs SV-BR-1-GM (an irradiated allogeneic breast cancer cell-line vaccine engineered to secrete GM-CSF; given as IFNγ-stimulated vs unstimulated formulations) with PD-1 checkpoint inhibition (pembrolizumab…
NCT06072612 - Trial result
Breast cancer
Alpelisib (PI3Kα) benefit tracks with FGFR1/2 alterations and low TMB in SOLAR-1
Alpelisib is an oral PI3Kα-selective inhibitor combined with fulvestrant, an estrogen-receptor degrader, for HR+/HER2− advanced breast cancer with PIK3CA-altered disease. In this retrospective SOLAR-1 Phase 3…
NCT02437318 - Trial result
Breast cancer
Abbreviated THP (paclitaxel+trastuzumab+pertuzumab) drives 99% 5-year EFS in stage II–III HER2+ breast cancer
In the single-arm Phase 2 DAPHNe trial secondary analysis (NCT03716180), patients with stage II–III ERBB2(HER2)-positive breast cancer received 12 weeks of neoadjuvant paclitaxel plus dual HER2 blockade with…
NCT03716180 - Trial result
Breast cancer
HER2-ultralow rescoring finds ~45% prevalence inside “HER2-0” advanced breast cancer
HER2-ultralow refers to IHC 0 tumors with faint/incomplete membrane staining, a boundary that may matter as trastuzumab deruxtecan extends HER2-directed ADC activity below classic HER2-low disease. In a Mayo Clinic…
- Trial result
Breast cancer
Concurrent boost (SIB) during whole-breast RT matches sequential boost control in high-risk early breast cancer, shortening treatment time
NRG/RTOG 1005 tested whether delivering the lumpectomy-cavity boost concurrently (a simultaneous integrated boost using 3D-CRT/IMRT) could maintain local control versus the standard sequential boost delivered after…
- Trial result
Breast cancer
MammaPrint H2 (70-gene signature) flags anthracycline benefit in HR+/HER2− early breast cancer
MammaPrint is a 70-gene prognostic signature; in FLEX real-world, prospectively collected data, the investigators asked whether its High-Risk 1 (H1) vs High-Risk 2 (H2) subgroups predict incremental benefit from…
- Trial result
Breast cancer
SUBITO: Olaparib (PARP inhibitor) matches IACT (alkylator + auto-SCT) for 4-year OS in stage III HRD breast cancer
SUBITO (Phase 3, open-label; NCT02810743) randomized newly diagnosed stage IIIA–C, HER2-negative, HRD breast cancer (n=174; median age 42; 25%–32% gBRCA1/2+) to intensified alkylating chemotherapy with autologous…
NCT02810743 - Trial result
Breast cancer
NRG/NSABP B-35 (tamoxifen vs anastrozole) suggests “close” DCIS margins don’t meaningfully worsen IBTR with WBI
In the Phase 3, double-blind NSABP B-35 trial (NCT00053898), 3104 postmenopausal women with HR-positive DCIS underwent lumpectomy + whole-breast irradiation (WBI) and were randomized to 5 years of tamoxifen (SERM) vs…
NCT00053898 - Trial result
Lymphoma
Brentuximab vedotin (CD30 ADC) + AVEPC lifts PFS in pediatric stage IV cHL—except bone marrow-only disease
In COG AHOD1331 (NCT02166463), 2–21-year-olds with high-risk classic Hodgkin lymphoma and centrally PET-CT–confirmed stage IV disease (n=340; median age 15) were randomized to 5 cycles of ABVE-PC…
NCT02166463 - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20) + R2 delivers higher CR/OS vs real‑world R2/CIT in R/R follicular lymphoma
Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody; here it was combined with lenalidomide (immunomodulatory agent) plus rituximab (anti‑CD20) as a chemotherapy-free regimen. In an adjusted comparative…
NCT04663347 - Trial result
Lymphoma
Epcoritamab (CD3×CD20 bispecific) hits early MRD-negativity in R/R FL—PFS signal strengthens by C3D1
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody evaluated as monotherapy in the EPCORE® NHL-1 Phase 1/2 study (NCT03625037) in relapsed/refractory follicular lymphoma after ≥2 prior lines;…
NCT03625037 - Trial result
Lymphoma
Ibrutinib (BTK inhibitor) + rituximab extends PFS but adds toxicity in chemo-ineligible 1L follicular lymphoma
Ibrutinib is an oral Bruton tyrosine kinase (BTK) inhibitor combined here with anti-CD20 rituximab as a chemotherapy-free first-line regimen. In the randomized, double-blind Phase 3 PERSPECTIVE trial (NCT02947347) in…
NCT02947347 - Trial result
Lymphoma
R2-based frontline FL: FLIPI24 flags high-risk patients with lower CR30 and 5-year PFS
FLIPI24 (a prognostic model for newly diagnosed follicular lymphoma) was evaluated in a pooled MD Anderson cohort of first-line, “chemo-free” immunotherapy regimens built around CD20 antibodies plus the…
NCT00695786 - Trial result
Lymphoma
Epcoritamab (CD3×CD20 bispecific) delivers 57.6% CR as chemo-free 1L option in anthracycline-ineligible DLBCL
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody evaluated as fixed-duration first-line therapy (± lenalidomide) in the open-label randomized Phase 2 EPCORE DLBCL-3 trial (NCT05660967) for…
NCT05660967 - Trial result
Lymphoma
Glofitamab (CD20xCD3) + polatuzumab vedotin (CD79b ADC) blunts high-risk biology signals in R/R LBCL biomarker analysis
Glofitamab is a CD20xCD3 T-cell–engaging bispecific antibody and polatuzumab vedotin is a CD79b-directed ADC (MMAE payload); this exploratory analysis compared tumor RNAseq and peripheral T-cell pharmacodynamics for…
NCT03533283 - Trial result Spotlight
Multiple myeloma
Linvoseltamab (BCMA×CD3) tops elranatamab on ORR/≥CR in unanchored MAIC of TCE RRMM
Linvoseltamab is an off-the-shelf BCMA×CD3 T-cell–engaging bispecific antibody compared here with elranatamab, another BCMA×CD3 bispecific, using an unanchored matching-adjusted indirect comparison across LINKER-MM1…
NCT03761108 - Trial result Spotlight
Multiple myeloma
Talquetamab (GPRC5D×CD3) + daratumumab ± pomalidomide sharply improves 24-mo PFS in RRMM
Talquetamab is a GPRC5D×CD3 T-cell–redirecting bispecific antibody, combined here with daratumumab, an anti-CD38 monoclonal antibody, with or without pomalidomide, an immunomodulatory agent. In the Phase 3…
NCT05455320 - New trial
Skin cancer (non-melanoma)
Phase 2 cemiplimab PD-1 checkpoint inhibitor with standardized immunosuppression in KTR advanced cSCC
Washington University School of Medicine’s CONTRAC-2 is a Phase 2, multicenter, open-label, single-arm trial using Simon’s optimal two-stage design to test whether cemiplimab (Regeneron Pharmaceuticals/Sanofi; a…
NCT07715734 Exploratory - New trial
Non-small cell lung cancer
Phase 2 cemiplimab PD-1 inhibitor plus platinum doublet chemo as neoadjuvant therapy in stage I NSCLC.
This Medical University of South Carolina (MUSC) investigator-initiated Phase 2 study tests whether adding cemiplimab (Libtayo; Regeneron Pharmaceuticals + Sanofi), a PD-1 (CD279)–blocking monoclonal antibody that…
NCT07720167 Exploratory - New trial Spotlight
Prostate cancer
Phase 3 rinzimetostat (ORIC-944) EED/PRC2 inhibitor + darolutamide AR antagonist in post-abiraterone mCRPC
ORIC Pharmaceuticals’ Himalayas-1 (NCT07723248) is a randomized, open-label Phase 3 study in metastatic castration-resistant prostate cancer (mCRPC) that has progressed after abiraterone acetate, testing whether…
NCT07723248 Registrational - New trial
Prostate cancer
Phase 3 177Lu vipivotide tetraxetan PSMA-targeted beta-emitting radioligand with adaptive dosing (RECIPROCAL)
Alliance for Clinical Trials in Oncology’s RECIPROCAL (A032304; NCT07200830) is a randomized Phase 3 strategy trial asking whether *when* to give additional doses of 177Lu vipivotide tetraxetan (Novartis’…
NCT07200830 Registrational
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.